maria luz calibo
Oct 6, 2011

U heads for ‘patent cliff’ | mndaily.com - Serving the University of Minnesota Community Since 1900

The University of Minnesota’s research community will be out of a big chunk of spending money as patents on a blockbuster HIV drug expire. The school has made more than $350 million off a drug invented on campus in the 1980s, but as the patents expire, those royalties are dwindling toward zero. And that means fewer investments into research.